In a nutshell This study looked at the effectiveness of reducing the dose of imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML). Researchers found that a lower dose of imatinib can achieve the same result as a high dose in most patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to...
Read MoreOngoing treatment(s)-Biological therapy Posts on Medivizor
Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?
In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...
Read MoreEvaluating the safety of ibrutinib in leukemia and lymphoma
In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...
Read MoreCyroablation for the treatment of early stage prostate cancer
In a nutshell This study evaluated the long-term safety and effectiveness of cryoablation (a process that uses extreme cold to destroy tissue) for patients with early prostate cancer. This study found that cryoablation is safe and effective for early-stage prostate cancer. Some background Cryoablation is a treatment option for early-stage prostate...
Read MorePonatinib as a second-line treatment for chronic-phase chronic myeloid leukemia
In a nutshell This study aimed to investigate if ponatinib is a suitable second-line treatment option for patients with chronic-phase chronic myeloid leukemia. This study concluded that ponatinib is a suitable option for these patients. Some background Ponatinib (Iclusig) is a tyrosine kinase inhibitor (TKI). TKIs work by blocking proteins...
Read MoreCAR-T cell therapy and infection risk
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read MoreGender affects outcomes of rituximab-based treatment
In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy. Some background Men are more likely to develop CLL than women....
Read MoreWhat are the new immunotherapy options for acute leukemia patients?
In a nutshell This review aimed to give an overview of the new types of immunotherapy that are available for adults with acute leukemia (AL). This review concluded that immunotherapies will continue to be used and developed for cancer treatment. Some background Acute myeloid leukemia (AML) occurs when abnormal myeloblasts are produced....
Read MoreAre Some Metastatic Lung Cancer Patients Outliving Prognosis?
Video information: Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact quality of life, rapid research to patients who are outliving their original prognosis, Dr. Carbone weighs in on...
Read MoreASCO 2017: Updates on Small Cell Lung Cancer Treatment and Research
Video information: At the 2017 ASCO meeting in Chicago, Dr. George Simon and Dr. David Carbone talk about news and progress in small cell lung cancer. Dr. Simon goes into detail on some new promising approaches and current studies for small cell lung cancer treatment, adding "these are some of the newer, in my opinion, more exciting approaches...
Read MoreTargeted therapies: Ibrutinib appears superior to idelalisib as first treatment
In a nutshell This study examined the order of treatment with ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (ABT-199) for chronic lymphocytic leukemia (CLL). Researchers concluded that ibrutinib appears superior to idelalisib as first treatment. Some background Early studies are reporting promising results with targeted therapies for...
Read MoreCetuximab as a second line treatment in metastatic colorectal cancer
In a nutshell This study investigated the effectiveness of the chemotherapy FOLFOX plus cetuximab (Erbitux), after cancer progression with FOLFIRI plus cetuximab. Researchers suggested that FOLFOX plus cetuximab is an important treatment option in non-KRAS mutated metastatic (spread to other parts of the body) colorectal cancer. Some background...
Read More
